Skip to content

Revvity RVTY JAPAN — Revenue from Contract with Customer, Excluding Assessed Tax

Discontinued — last reported Q4 '20

Similar metrics at other companies

Cytokinetics logo
CYTKJP — Revenue
$0
Advanced Energy Industries logo
AEISJP — Revenue
$51.2M+207%
Onto Innovation logo
ONTOJP — Revenue
$16.88M+102%
Synopsys logo
SNPSJP — Revenue
$77.82M+18.4%
Lattice Semiconductor logo
LSCCJP — Revenue
$2.35M-81.9%
Planet Labs logo
PLJP — Revenue
$9.5M

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$11.16B-22.9%
Enterprise value$14.24B-13.7%
P/E46.5×-4.0×
P/S3.8×-1.4×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Revvity’s 10-K, filed March 2, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does JAPAN — revenue from contract with customer, excluding assessed tax mean?
The total net sales revenue earned specifically from customers located in Japan.
How do you interpret JAPAN — revenue from contract with customer, excluding assessed tax?
An increase suggests successful market expansion, strong product adoption, or favorable economic conditions in Japan, while a decrease may indicate heightened competition, regulatory headwinds, or a slowdown in local demand for life science and diagnostic tools.
How does JAPAN — revenue from contract with customer, excluding assessed tax compare across companies?
Comparable to regional revenue disclosures provided by other global life science and diagnostics firms, which often break down performance by major geographic territories to highlight regional growth trends.